相关实验视频
Updated: Jun 11, 2025

04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
309
对肥胖的药理疗法的方法不断发展
Ariana M Chao1, Simeon Taylor2, Molly Moore3
1Johns Hopkins School of Nursing, Baltimore, Maryland, USA;
Annual review of pharmacology and toxicology
|September 30, 2024
概括
新的抗肥胖药物 (AOM) 为肥胖提供了扩展的治疗选择,肥胖是一个日益严重的全球健康问题. 本综述涵盖了当前和新兴的AOM,重点关注基于激素的疗法及其对体重管理的影响.
科学领域:
- 内分泌学和新陈代谢学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 肥胖是一个重要的全球健康挑战,具有复杂的生理基础.
- 了解肥胖生理学和减肥机制已经确定了新的治疗目标.
- 现有的体重管理策略需要持续创新,以满足患者的需求.
研究的目的:
- 审查当前的抗肥胖药物 (AOMs) 的情况.
- 突出新兴的治疗类别,特别是基于激素和激素的疗法.
- 讨论未来的AOM管道及其对肥胖管理的影响.
主要方法:
- 关于肥胖和减肥的生理机制的文献综述.
- 对目前批准的抗肥胖药物的分析.
- 在临床开发管道中对AOM的调查.
- 讨论因克雷丁和营养刺激的基于激素的疗法.
主要成果:
- 几种新的AOM正在临床试验中取得进展.
- 基于英克雷丁和营养刺激的激素疗法显示出显著的前景.
- 管道包括用于体重管理的各种行动机制.
结论:
- 肥胖管理领域正在迅速发展,有新的药理选择.
- 了解荷尔蒙调节的进步正在推动开发有效的AOM.
- 预计未来的治疗方法将提供更个性化,更有效的体重管理解决方案.
相关概念视频
Drug Therapy
39
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
39
Diabetes: Management and Pharmacotherapy
243
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
243
Glucagon-like Receptor Agonists
302
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
302
Antidepressant Drugs: MAOIs and Other Agents
200
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
200
Drug Administration and Therapy Phases: Overview
415
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
415
Model Approaches for Pharmacokinetic Data: Physiological Models
36
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
36

